Table 1.
Main differences between the human MNT, other human MXD proteins, MGA, and MYC. The sizes of the proteins are the largest canonical forms, according to the UniProt database. Aa, amino acids; ND, not done; DEL, deletions; AMP, amplifications; MUT, mutations; CTCL, Cutaneous T-cell lymphoma; MB, medulloblastoma; SS, Sezary Syndrome; ALL, acute lymphoblastic leukemia.
| MNT | MXD1 | MXI1 (MXD2) | MXD3 | MXD4 | MYC | References | |
|---|---|---|---|---|---|---|---|
| Protein size | 582 aa | 221 aa | 228 aa | 206 aa | 209 aa | 439 aa | Uniprot database |
| P-rich sequences | Yes | No | No | No | No | Yes | [2] |
| Phenotype of KO mice | Perinatally lethal/Craniofacial abnormalities | Viable/Increased immature granulocyte progenitors | Viable/Hyperplasia | Viable/Enhanced sensitivity to apoptotic stimuli | ND | Embryonic lethal E9.5–E10.5 | [11,12,13,14] |
| Proximal MYC Network interactors | MNT, MAX, MLX | MAX, MLX | MAX | MAX | MAX, MLX | MAX | Reviewed in [15] |
| Expression in cells | Quiescent and proliferating | Quiescent | Quiescent and proliferating * | Proliferating (S-phase) | Quiescent | Proliferating | Reviewed in [15] |
| Pan-cancer copy number alterations (%) | DEL 10 AMP 3 MUT 1 |
DEL 2 AMP 6 MUT < 0.5 |
DEL 8 AMP 4 MUT < 0.5 |
DEL 7 AMP 8 MUT < 0.5 |
DEL 6 AMP 5 MUT < 0.5 |
DEL 2 AMP 21 MUT 1 |
[16] |
| Involvement in human cancer | DEL in CTCL-SS and ALL. Reduced expression in MB | None or weak | None or weak | None or weak | None or weak | Strongly, 70% of tumors have deregulation | [17,18,19,20,21,22] |
* central nervous system, epidermis, and the myeloid lineage.